Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study
Authors
Keywords
Metastatic pancreatic adenocarcinoma, Gemcitabine, Nab-paclitaxel, Real-life, First-line chemotherapy, Survival
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-11-29
DOI
10.1186/s12885-018-5101-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- European cancer mortality predictions for the year 2018 with focus on colorectal cancer
- (2018) M Malvezzi et al. ANNALS OF ONCOLOGY
- Trends in net survival from pancreatic cancer in six European Latin countries
- (2017) Anne-Marie Bouvier et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations
- (2017) Lei Huang et al. GUT
- Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis
- (2017) AnaFernández Montes et al. Journal of Cancer Research and Therapeutics
- NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
- (2016) Ferdinando De Vita et al. BMC CANCER
- Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Volker Ellenrieder et al. DIGESTION
- Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study
- (2016) Nha Le et al. DIGESTION
- Current standards and new innovative approaches for treatment of pancreatic cancer
- (2016) Thierry Conroy et al. EUROPEAN JOURNAL OF CANCER
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
- (2016) Marwan Ghosn et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.
- (2015) Guido Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.
- (2015) Guido Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
- (2014) T Hamada et al. BRITISH JOURNAL OF CANCER
- Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study
- (2013) Roberta De Angelis et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started